Disease · MONDO_0007243
Burkitt lymphoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Burkitt lymphoma. Diseases, record MONDO_0007243. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007243
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Burkitt lymphoma/leukaemia, Burkitt lymphoma/leukemia, Burkitt's lymphoma, Burkitt's tumor, Burkitt's tumor or lymphoma, Burkitt's tumour, Burkitt's tumour or lymphoma, Burkitts lymphoma, burkitt lymphoma, somatic, malignant lymphoma, Burkitt's type, small non-cleaved cell lymphoma, small non-cleaved cell lymphoma, Burkitt's type
- Open Targets
Drugs53
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 3 | ClinicalTrials.gov | 18 | 18 | 18 | Drugs and targets |
| ETOPOSIDE | CHEMBL44657 | Small molecule | Phase 3 | ClinicalTrials.gov | 12 | 12 | 12 | Drugs and targets |
| VINCRISTINE | CHEMBL90555 | Small molecule | Phase 3 | ClinicalTrials.gov | 12 | 12 | 12 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| IFOSFAMIDE | CHEMBL1024 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IBRUTINIB | CHEMBL1873475 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IDARUBICIN | CHEMBL1117 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INSULIN ASPART | CHEMBL1201496 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INSULIN GLARGINE | CHEMBL1201497 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 53
See all 53 drugsTargets100
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CD19 | B-lymphocyte antigen CD19 | 5 | B-lymphocyte antigen CD19 binding agent | Phase 2 | https://conductscience.org/library/genes/930 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 5 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| TOP2A | DNA topoisomerase 2-alpha | 5 | DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor | Phase 3 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| MS4A1 | B-lymphocyte antigen CD20 | 4 | B-lymphocyte antigen CD20 binding agent | Phase 3 | https://conductscience.org/library/genes/931 | Drugs and targets |
| TUBA1A | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/112714 | Drugs and targets |
| TUBA4A | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7277 | Drugs and targets |
1 to 10 of 100
See all 100 targetsTrials40
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00001337 | Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma | Phase 2 | 348 | 2025-06-12 | Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma, Anaplastic Large-Cell Lymphoma, Gray Zone Lymphoma | CYCLOPHOSPHAMIDE, DOXORUBICIN, ETOPOSIDE, PREDNISONE, RITUXIMAB, VINCRISTINE | Its record names the disease | ClinicalTrials.gov |
| NCT00305682 | Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant | Phase 2 | 295 | 2020-11-02 | Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes | CYCLOPHOSPHAMIDE, FLUDARABINE, MYCOPHENOLATE MOFETIL, SIROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT01092182 | Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma | Phase 2 | 194 | 2021-10-19 | Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma | CYCLOPHOSPHAMIDE, DOXORUBICIN, ETOPOSIDE, PREDNISONE, RITUXIMAB, VINCRISTINE | Its record names the disease | ClinicalTrials.gov |
| NCT01193842 | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | Phase 1/2 | 107 | 2018-06-12 | AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage I Grade 3 Follicular Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, HIV Infection, Plasmablastic Lymphoma, Primary Effusion Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma | CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, PREDNISONE, RITUXIMAB, VINCRISTINE SULFATE, VORINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00039130 | Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia | Phase 2 | 105 | 2014-10-22 | Leukemia, Lymphoma | ALLOPURINOL, CYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, FILGRASTIM, IFOSFAMIDE, LEUCOVORIN CALCIUM, METHOTREXATE, PREDNISONE, RITUXIMAB, VINCRISTINE SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT02703272 | A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma | Phase 3 | 72 | 2022-12-02 | Lymphoma, Non-Hodgkin | CARBOPLATIN, DEXAMETHASONE, ETOPOSIDE, IBRUTINIB, IDARUBICIN, IFOSFAMIDE, RITUXIMAB, VINCRISTINE | Its record names the disease | ClinicalTrials.gov |
| NCT00669877 | Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma | Phase 2 | 56 | 2018-05-16 | Burkitt's Lymphoma, Burkitt'S-like Lymphoma | CYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, RITUXIMAB, VINCRISTINE | Its record names the disease | ClinicalTrials.gov |
| NCT01791595 | A Phase I Trial of AZD3965 in Patients With Advanced Cancer | Phase 1 | 53 | 2022-04-11 | Adult Solid Tumor, Diffuse Large B Cell Lymphoma, Burkitt Lymphoma | AZD3965 | Its record names the disease | ClinicalTrials.gov |
| NCT00500240 | Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL) | Phase 3 | 52 | 2014-08-07 | Leukemia, Lymphoma | INSULIN ASPART, INSULIN GLARGINE | Its record names the disease | ClinicalTrials.gov |
| NCT00807495 | Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma | Phase 2 | 48 | 2018-03-27 | Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma, T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma, Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component | ALISERTIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 40
See all 40 trialsComparisons in its trials19
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
With EPOCH-R (Etoposide, Doxorubicin, Prednisone, Cyclophosphamide and Rituximab) vs EPOCH Alone (Etoposide, Doxorubicin, Prednisone, and Cyclophosphamide): Overall Response (Complete Response + Partial Response) | 216 of 235 | 94 of 112 | 347 | NCT00001337 | Trial comparisons |
With EPOCH-R (Etoposide, Doxorubicin, Prednisone, Cyclophosphamide and Rituximab) vs EPOCH Alone (Etoposide, Doxorubicin, Prednisone, and Cyclophosphamide): Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | 235 of 235 | 112 of 112 | 347 | NCT00001337 | Trial comparisons |
| With EPOCH-R (Etoposide, Doxorubicin, Prednisone, Cyclophosphamide and Rituximab) vs EPOCH Alone (Etoposide, Doxorubicin, Prednisone, and Cyclophosphamide): Progression Free Survival (PFS) | 73 of 235 | 41 of 112 | 347 | NCT00001337 | Trial comparisons |
| With EPOCH-R (Etoposide, Doxorubicin, Prednisone, Cyclophosphamide and Rituximab) vs EPOCH Alone (Etoposide, Doxorubicin, Prednisone, and Cyclophosphamide): deaths from any cause | 28 of 235 | 13 of 112 | 347 | NCT00001337 | Trial comparisons |
| With EPOCH-R (Etoposide, Doxorubicin, Prednisone, Cyclophosphamide and Rituximab) vs EPOCH Alone (Etoposide, Doxorubicin, Prednisone, and Cyclophosphamide): serious adverse events | 146 of 235 | 44 of 112 | 347 | NCT00001337 | Trial comparisons |
| Tisagenlecleucel - Post-infusion vs Tisagenlecleucel - Pre-infusion Deaths: deaths from any cause | 17 of 33 | 1 of 34 | 67 | NCT03610724 | Trial comparisons |
| Conventional Care vs Intensive Insulin: serious adverse events | 9 of 25 | 10 of 26 | 51 | NCT00500240 | Trial comparisons |
| Part 2: Ibrutinib+CIT (RICE or RVICI) vs Part 2: Chemoimmunotherapy: Part 2: Number of Participants Who Proceeded to Stem Cell Transplantation | 13 of 35 | 7 of 16 | 51 | NCT02703272 | Trial comparisons |
| Regimen A (R-CODOX-M Chemotherapy) vs Regimen B (Rituximab and IVAC Chemotherapy): serious adverse events | 0 of 2 | 23 of 32 | 34 | NCT00392834 | Trial comparisons |
| Part 1: Ibrutinib vs Part 2: Ibrutinib: Part 1 and Part 2: Number of Participants With Greater Than (>) 90% Bruton's Tyrosine Kinase (BTK) Occupancy | 5 of 15 | 5 of 13 | 28 | NCT02703272 | Trial comparisons |
1 to 10 of 19
See all 19 comparisons in its trialsPapers from its trials34
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007243
GET https://conductscience.org/api/diseases/v1/MONDO_0007243/drugs?page=2